Transaction to Result in 43% Reduction of Outstanding Common Shares

Houston, TX - (NewMediaWire) - April 30, 2019 - Visual Healthcare Corp. (OTC PINK: VSHC) announces today that a share exchange agreement has been signed for the return to the company of 230 million shares of Visual Healthcare Corp. common stock.  The shares were initially issued to Ithaca Scientific Ventures, Inc. and were pledged as collateral on a loan to a third party. Mr. Gerard Dab, former CEO of Visual Healthcare Corp. and current CEO of VisualMED Clinical Solutions Corp., was instrumental in facilitating the transaction between the two parties.  The company plans to cancel the shares once the transaction is complete.

Mr. Linh Nguyen, CEO, states, “We would like to thank Mr. Dab for his cooperation and professionalism in bringing the two parties together and helping us reach a mutually-beneficial agreement.  We are pleased to have been able to resolve this issue without a long, drawn out legal process while also reducing any risk of dilution to current shareholders.”

“These agreements go a long way to help protect the interest of the many long-term shareholders,” concludes Mr. Gerard Dab. “We are excited about the new direction of the company and will continue to cooperate with the new management team to increase shareholder value.”

Details of the agreement will be released through OTC Markets once the transaction is finalized and all obligations of each party have been satisfied.  With the retirement of these shares, Visual Healthcare Corp. will have approximately 311 million issued and outstanding shares of common stock.  This equates to a reduction of approximately 43% of our current outstanding shares.

Our focus now turns to the completion of the remaining filings in order to get current with OTC Markets.  We anticipate this task to be completed in the coming days, at which time we will begin finalizing paperwork to close on the first of our many planned acquisitions. Thank you to all shareholders for your patience and continued support throughout this process.  

About LTN Capital Ventures

LTN Capital invests in emerging growth companies in the energy, oil & gas, and industrial manufacturing sectors. Our management team is comprised of executives with over 20 years of experience in the oil and gas industry and has executed contracts with global reach. The company’s growth plan is to not only expand its business revenues but will also grow through acquisition roll-up of complementary businesses in the energy sector.

To subscribe to company updates, please visit the Company's website at www.ltncap.com  -- also follow VSHC at https://twitter.com/LTNCap.

About Hi-Alloy Valve

Hi-Alloy Valve (HAV) is a leading supplier of valves for various energy industries. The primary focus of the company is on wellhead (API 6A upstream) and pipeline (API 6D midstream) valves for the oil and gas industry. HAV is a certified ISO 9001 and API Q1 company that serve the global energy market by delivering high quality valves with exceptional turnaround time.

For more information about Hi-Alloy Valve visit - www.hialloyvalve.com or contact the Company directly at 1-713-856-9777. Make sure to follow the company on Twitter at www.twitter.com/hialloyvalve.

Contact Information

VSHC Shareholder/Investor inquiries can be directed to:

LTN Capital Ventures
1-713-849-1300
investors@ltncap.com

About VisualMED Clinical Solutions

VisualMED,  a clinical information company, owns a portfolio of valuable intellectual property. The company’s university affiliates are world leaders in Artificial Intelligence which help to support our process to adapt some of our intelligent applications for home use. Patients will be able to monitor serious health and medical issues, helping to reduce medical errors and negligence that put millions of patients in harm’s way every year in North America.

For more information about VisualMED Clinical Solutions, contact the Company directly at 1-438-501-6500.

Contact Information

VMCS Shareholder/Investor inquiries can be directed to:

VisualMED Clinical Solutions
cliniscience@gmail.com
1-438-501-6500

Safe Harbor Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that would cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements.